Tactile Systems Technology, Inc. · NASDAQ:TCMD

Tactile Systems Technology — Tactile Medical — Investor Presentation (November 2026)

36 slides from Tactile Systems Technology's investor presentation, Nov 2, 2026

  1. Slide 1: Investor Presentation

    Investor Presentation November 2, 2026 NASDAQ: TCMD

  2. Slide 2: Forward-Looking Statements & Non-GAAP Financial Information

    Forward-Looking Statements & Non-GAAP Financial Information Forward Looking Statements This presentation contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,

  3. Slide 3: Revealing & Treating Patients with Underserved Chronic Conditions

    Revealing & Treating Patients with Underserved Chronic Conditions… …including: Chronic Swelling/ Lymphatic Dysfunction Inflammatory Lung Disease TACTILE MEDICAL | 3

  4. Slide 4: Leadership Team

    Leadership Team Decades of Combined Experience and Leadership in the Medical Device Industry Sheri Dodd Elaine Birkemeyer Ben Amel Steve Kiewiet Janelle Strop Aaron Snodgrass Nicolaus Wilson Chief Executive Chief Financial Chief Information Chief Operating Chief Human SVP, Sales SVP, Marketing & Off

  5. Slide 5: Underpenetrated, Large TAM; Scaled, Market Leading Position

    Underpenetrated, $10B ~2.5M ~25M Large TAM Total Addressable Market1 Diagnosed Populations2 Undiagnosed Populations3 Scaled, Market >95,000 $330M Leading Position Patients Served in 2025 2025 Total Revenue Demonstrated 76% $45M $43M Profitability 2025 Gross Margin 2025 Adj. EBITDA4 2025 Operating Ca

  6. Slide 6: Chronic & Progressive, Underdiagnosed & Undertreated Disease States

    Chronic & Progressive, Underdiagnosed & Undertreated Disease States Significant Gaps in Both Diagnosis and 2M 1 Access to Effective Treatment 500K 4 DIAGNOSED DIAGNOSED LYMPHEDEMA I N T H E BRONCHIECTASIS I N U.S. THE U.S. 20M+ UNDIAGNOSED 2,3 4.4M 5,6 IN THE U.S. UNDIAGNOSED IN THE U.S. 1. Data on

  7. Slide 7: Significant Opportunity to Improve Access to Critically Underserved Patient Populations

    Significant Opportunity to Improve Access to Critically Underserved Patient Populations LYMPHEDEMA BRONCHIECTASIS $5B+ CURRENT ADDRESSAB LE $5B+ CURRENT ADDRESSAB LE MARKET $10B+ TOTAL ADDRESSABLE MARKET MARKET* Gaps in Patient Education and Access Present an Opportunity to Deliver Patient-Centric S

  8. Slide 8: Significant Opportunity to Improve Access to Critically Underserved Patient Populations

    Significant Opportunity to Improve Access to Critically Underserved Patient Populations LYMPHEDEMA BRONCHIECTASIS $5B+ CURRENT ADDRESSAB LE $5B+ CURRENT ADDRESSAB LE MARKET $10B+ TOTAL ADDRESSABLE MARKET MARKET* Gaps in Patient Education and Access Present an Opportunity to Deliver Patient-Centric S

  9. Slide 9: Lymphedema Has Many Causes and Affects People of all Backgrounds

    Lymphedema Has Many Causes and Affects People of all Backgrounds What is It? How Does it Occur? The lymphatic system enables the transport of fluids containing  Chronic venous  Trauma infection-fighting white blood cells. insufficiency (CVI)  Surgery When the lymphatic system is damaged or impair

  10. Slide 10: Less Than 10% of Diagnosed Patients Receive a Solution to Treat

    As a Result, Less Than 10% of Diagnosed Patients Receive a Solution to Treat Their Symptoms Lymphedema Symptoms Include:  Cellulitis  Skin changes  Swelling  Pain & tightness  Hard-to-heal wounds  Dysphagia  Limb heaviness  Inability to swallow  Fibrosis  Limited range of motion Most patie

  11. Slide 11: The Care Journey is Long and Complex, with Countless Friction Points

    The Care Journey is Long and Complex, with Countless Friction Points Undiagnosed Diagnosis Treatment Pre-Awareness Awareness Conservative Therapy ICP* Order Process Home-Based Therapy Limited disease education Conservative therapy delays care Administrative barriers Variable patient experience • 60%

  12. Slide 12: Tactile Medical Delivers Differentiated Solutions: Product and Service

    Tactile Medical Delivers Differentiated Solutions: Product and Service Legacy Systems Recent & Upcoming Innovation Basic Device: ENTRE® PLUS Basic Device: NIMBL® Convenient, at-home Smaller, lighter, and portable treatment for lymphedema solution for use at home or on the and chronic swelling design

  13. Slide 13: Proven Clinical Efficacy Drives Consistent and Effective Therapy

    Proven Clinical Efficacy Drives Consistent and Effective Therapy 88% 85% 96% 37% experienced lower improved ability to satisfaction with reduction in total limb volume perform activities of Flexitouch lymphedema-related reduction with daily living1 treatment2 costs per patient3 Flexitouch1 Existing

  14. Slide 14: Flexitouch Plus Further Validated in Treating Head & Neck Cancer-Related Lymphedema

    Flexitouch Plus Further Validated in Treating Head & Neck Cancer-Related Lymphedema Data Overview • Six-month results from Tactile Medical’s clinical trial examining the effectiveness of Flexitouch Plus vs. usual care in treating lymphedema among head and neck cancer survivors • Data shows sustained

  15. Slide 15: Kylee App Enables Personalized Treatment and Patient Engagement

    Kylee App Enables Personalized Treatment and Patient Engagement Learn Personalized information to help patients understand their condition Track Symptom & treatment tracking to understand how therapy is progressing Share Converts treatment data into reports that can be shared with care team TACTILE

  16. Slide 16: Earlier, More Objective Identification of Disease with LymphaTech

    Earlier, More Objective Identification of Disease to Expand Access to Care with LymphaTech About the LymphaTech Technology Role in Our Strategy Long-Term Vision for Tactile • FDA-cleared digital platform for fluid volume • Supports earlier, more consistent disease • Now – in use and generating reven

  17. Slide 17: Removing Friction Points Across the Care Continuum

    Removing Friction Points Across the Care Continuum: Strategic Investment Supported by Structural Tailwinds Undiagnosed Diagnosis Treatment Pre-Awareness Awareness Conservative Therapy ICP* Order Process Home-Based Therapy Limited disease education Conservative therapy delays care Administrative barr

  18. Slide 18: Market Leadership and Robust Sales Force Strengthened By Distinct Barriers to Entry

    Market Leadership and Robust Sales Force Further Strengthened By Distinct Barriers to Entry • Integrated direct-to-patient/provider model Vertically Integrated Model  • In-house DME operations with oversight of entire order process: manufacturing, claims processing, collections, and RCM • Efficient

  19. Slide 19: Lymphedema Market Fundamentals & Strategy

    Lymphedema Market Fundamentals & Strategy ~145K 1 Number of diagnosed patients treated annually Diagnosed patients treated with a PCD or NPCD with PCD/NPCD is growing ~10%1 2M1 Addressable diagnosed U.S. patients Significant annual addressable market without PCD or NPCD treatment Near-term commercia

  20. Slide 20: Strategic Priorities to Drive Sustainable & Profitable Lymphedema Growth

    Strategic Priorities to Drive Sustainable & Profitable Lymphedema Growth More Patients Diagnosed and Referred  More Referrals Reaching Therapy  More Patients Served Expand Access Create Value Across the Expand Treatment to Care Patient Journey Options  Identify more patients  Convert more eligib

  21. Slide 21: Owning the Space with Lymphedema Solutions that Improve Patient's Lives

    Owning the Space with Lymphedema Solutions that Improve Patient’s Lives #1*  CLINICA LLY PROVEN PNEUMATIC COMPRESSION DEVICES MARKET SHARE  EXPANDING CLINICA L EVIDENCE  LARGE SALES REACH $5B+* TOTA L A D D R E SSA B L E   SCALAB LE BACK OFFICE CAPABILITIES BROAD INSURAN CE COVERAGE MARKET  NE

  22. Slide 22: Significant Opportunity to Improve Access to Critically Underserved Patient Populations

    Significant Opportunity to Improve Access to Critically Underserved Patient Populations LYMPHEDEMA BRONCHIECTASIS $5B+ CURRENT ADDRESSAB LE $5B+ CURRENT ADDRESSAB LE MARKET $10B+ TOTAL ADDRESSABLE MARKET MARKET* Gaps in Patient Education and Access Present an Opportunity to Deliver Patient-Centric S

  23. Slide 23: Bronchiectasis is Among the Most Common Respiratory Diseases

    Bronchiectasis is Among the Most Common Respiratory Diseases What is It? Bronchiectasis is a complex respiratory disease that causes airways to be abnormally widened, inflamed, and scarred, leading to permanent damage. Damaged airways can no longer clear mucus and bacteria from airways and lungs, ca

  24. Slide 24: Too Many Bronchiectasis Patients are Not Receiving Access to Treatment

    Too Many Bronchiectasis Patients are Not Receiving Access to Quality-of-Life Restoring Treatment Routinely left untreated If treated, first-line options not effective for many patients L E F T U N T R E AT E D BASIC APPROACH S TA N D A R D O F C A R E  Antibiotics for  Chest physiotherapy  Common

  25. Slide 25: Advancing the Bronchiectasis Treatment Paradigm with Proven At-Home Therapy

    Tactile is Advancing the Bronchiectasis Treatment Paradigm with Proven At-Home Therapy NEXT-GENERATION AFFLOVEST® Next-generation AffloVest launched June 2026  High frequency chest wall oscillation (HFCWO) therapy  Lighter, more adjustable vest and redesigned controller improve comfort and ease of

  26. Slide 26: Leading the Market with Patient-Friendly Airway Clearance Therapy

    Leading the Market with Patient-Friendly Airway Clearance Therapy #1*  DIFFERENTIATED PORTABLE DESIGN MARKET SHARE  BROAD DME CHANNEL REACH $5B+ * TOTA L A D D R E SSA B L E  AFFLOVEST FITS COMPLEX RESPIRATORY PATIENT ALREADY ON-SERVICE MARKET  STRONG REIMBURSEMENT *Based on management estimates

  27. Slide 27: Well-Defined Go-to-Market Strategy

    Well-Defined Go-to-Market Strategy Lymphedema: Direct Sales Force Bronchiectasis: Indirect Sales Force Selling Through Established Call Points Selling Through DME1 Partners ~275M Vascular Practices Oncology Practices Respiratory DMEs Covered Lives Lymphatic Therapists Veterans Affairs Account Manage

  28. Slide 28: Recent Milestones

    Recent Milestones Multiple Product Launches & Operational Enhancements Fueling Continued Market Penetration and Profitable Growth 2024 2025 YTD 2026  Generated new clinical evidence among VA patients using Flexitouch®  Expanded Nimbl® System for lower extremity lymphedema conditions  Entered into

  29. Slide 29: Durable Revenue & Profit Growth with Increasing Operating Cash Flow

    Durable Revenue & Profit Growth with Increasing Operating Cash Flow ~16%* $329.5 $360 - $366 REVENUE CAGR $293.0 $274.4 $246.8 $208.1 $189.5 $187.1 $143.8 $109.3 $84.5 $50 - $29.7 $37.1 $44.8 $7.0 $9.8 $17.3 $25.3 $16.0 $17.7 $18.3 $52 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Guidance

  30. Slide 30: Investment Highlights

    Investment Highlights Leveraging Technology & Market Leadership to Deliver Profitable Growth ~$10B TAM* Strong Pipeline & Tech Strategy With significant greenfield Driving innovation, customer service, and operating leverage Broad Payer Support Extensive Distribution Reach With increasingly supporti

  31. Slide 31: Appendix

    Appendix TACTILE MEDICAL | 31

  32. Slide 32: Financial Results: Q3 2026 & 2025, FY'25 & FY'24

    Financial Results: Q3 2026 & 2025, FY’25 & FY’24 Three months ended September 30, Year Ended December 31, 3 MONTHS ENDED $ Millions 2026 2025 2025 2024 SEPTEMBER 30, 2026 $278.4 $259.4 Lymphedema products $81.8 $72.4 FINANCIAL SUMMARY: Airway clearance products $10.0 $13.4 $51.1 $33.6 Total revenues

  33. Slide 33: Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA

    Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA Years ended December 31 ($ Millions) 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 $ $ $ Net income (loss) $ 19.1 $ 17.0 $ 28.5 (17.9) (11.8) (0.6) $ 11.0 $ 6.6 $ 5.9 $ 2.9 Interest (income) expense, net (2.1) (1.3) 2.3 2.7 0.5

  34. Slide 34: Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA

    Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA Three Months Ended Increase September 30, (Decrease) (Dollars in millions) 2026 2025 $ % Net income $ 7.2 $ 8.2 $ (1.0) (13%) Interest (income) expense, net (0.5) (0.5) (0.1) 14% Income tax expense (benefit) 3.0 3.2 (0.3) (8%) Depreciatio

  35. Slide 35: Reconciliation of FY 2026 GAAP Net Income to Adjusted EBITDA Guidance

    Reconciliation of FY 2026 GAAP Net Income to Adjusted EBITDA Guidance Year ended December 31, 2026 (Dollars in millions) Low High Net income $ 24.1 $ 25.5 Interest (income) expense, net (2.4) (2.4) Income tax expense 9.4 9.9 Depreciation and amortization 7.3 7.3 Stock-based compensation 8.6 8.6 Acqu

  36. Slide 36: Select Comparisons from the Balance Sheet as of 9/30/2026 and 12/31/2025

    Select Comparisons from the Balance Sheet as of 9/30/2026 and 12/31/2025 Increase (Decrease) (Dollars in millions) 9/30/2026 12/31/2025 $ % Cash $ 75.1 $ 83.4 $ (8.3) (10)% Accounts receivable 48.3 43.9 4.4 10% Accounts receivable, non-current 0.0 0.0 0.0 0% Total accounts receivable 48.3 43.9 4.4 1

Tactile Medical — Investor Presentation (November 2026) on 6ix